ADMA Biologics saw its IBD SmartSelect Composite Rating jump to 96 Friday, up from 93 the day before.
The upgrade means the stock is now outperforming 96% of all other stocks in terms of key performance metrics and technical strength.
ADMA Biologics has now climbed above a proper buy zone after clearing the 4.07 entry in a cup with handle.
Lean How — And When — To Sell Stocks
The stock earns an 81 EPS Rating, which means its recent quarterly and annual earnings growth is outpacing 81% of all stocks.
Its Accumulation/Distribution Rating of C- shows a roughly equal amount of buying and selling by institutional investors over the last 13 weeks.
In Q3, the company reported 1,400% earnings-per-share growth. Top line growth was flat, matching the prior report's 78%.
ADMA Biologics holds the No. 2 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals is the No. 1-ranked stock within the group.
